Rheumatology:RA患者巨噬细胞的血清胆固醇负荷能力受血清阳性和C反应蛋白调节

2022-07-17 紫菀款冬 MedSci原创

探讨类风湿关节炎患者血清中的因子以及它们相互作用和影响巨噬细胞胆固醇负荷能力的机制。

目的:巨噬细胞内胆固醇过度积聚是动脉粥样硬化斑块形成的关键步骤。在此探讨类风湿关节炎(RA)患者血清中的因子以及它们相互作用和影响巨噬细胞胆固醇负荷能力(CLC)的机制。

方法:在104例RA患者的横断面观察队列中,与患者血清孵育后,测定CLC作为人类THP-1衍生巨噬细胞中的细胞内胆固醇含量。测定氧化低密度脂蛋白作为含apoB100颗粒(oxPL-apoB100)上的氧化磷脂含量。还定量了氧化低密度脂蛋白(anti-oxLDL)、前蛋白转化酶枯草溶菌素9(PCSK9)和高敏CRP的抗体含量。所有分析均根据动脉粥样硬化性心血管疾病(ASCVD)风险评分、肥胖、总低密度脂蛋白、他汀类药物使用、诊断年龄和抗oxLDL-IgM进行调整。

结果:OxPL-apoB100、抗oxLDL-IgG和PCSK9与CLC呈正相关(均p<0.020)。OxPL-apoB100仅直接影响双类风湿因子和抗瓜氨酸蛋白抗体阳性患者的CLC(非标准b[95%引导置信区间]=2.08[0.38–3.79])。oxPL-apoB100通过抗oxLDL-IgG对CLC的间接作用随着CRP水平的增加而增加(缓和调解指数 = 0.55 [0.05–1.17])。CRP还通过上调PCSK9调节oxPL-apoB100对CLC的另一间接作用,但仅在双重血清阳性患者中(条件间接作用 = 0.64 [0.13–1.30])。 

结论:氧化低密度脂蛋白可直接影响双血清阳性RA患者的CLC。根据CRP和血清阳性状态,通过抗oxLDL IgG和PCSK9的另外两条独立途径可能介导oxPL-apoB100对CLC的影响。如果外部验证,这些发现可能对心血管风险预防具有临床意义

文献来源:

Karpouzas GA, Papotti B, Ormseth SR, et al. Serum cholesterol loading capacity on macrophages is regulated by seropositivity and C-reactive protein in rheumatoid arthritis patients [published online ahead of print, 2022 Jul 9]. Rheumatology (Oxford). 2022;keac394. doi:10.1093/rheumatology/keac394

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062589, encodeId=15fc2062589ba, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Feb 14 01:18:58 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297865, encodeId=8fb7129e865f3, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Jul 15 15:18:58 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537827, encodeId=cf79153e82789, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bded12907571, createdName=lq0305, createdTime=Fri Jul 15 15:18:58 CST 2022, time=2022-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062589, encodeId=15fc2062589ba, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Feb 14 01:18:58 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297865, encodeId=8fb7129e865f3, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Jul 15 15:18:58 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537827, encodeId=cf79153e82789, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bded12907571, createdName=lq0305, createdTime=Fri Jul 15 15:18:58 CST 2022, time=2022-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062589, encodeId=15fc2062589ba, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Tue Feb 14 01:18:58 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297865, encodeId=8fb7129e865f3, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Fri Jul 15 15:18:58 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537827, encodeId=cf79153e82789, content=<a href='/topic/show?id=a53c894e978' target=_blank style='color:#2F92EE;'>#血清阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89479, encryptionId=a53c894e978, topicName=血清阳性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bded12907571, createdName=lq0305, createdTime=Fri Jul 15 15:18:58 CST 2022, time=2022-07-15, status=1, ipAttribution=)]

相关资讯

李菁教授:为什么甲氨蝶呤如此经典&甲氨蝶呤如何安全用药?

甲氨蝶呤作为风湿科经典的抗风湿药物,也是类风湿关节炎治疗研究的金标准。为什么甲氨蝶呤能有如此的“江湖地位”?

不止红斑狼疮!羟氯喹还可以治疗这些风湿病

细数羟氯喹在风湿免疫领域的使用。

Arthritis Res Ther: 靶向治疗对老年类风湿关节炎患者安全有效

HI患者总体IR随年龄增长而增加。在调整了患者特点和合并治疗后,TT组与MTX组相比,老年和高龄患者HI的风险没有升高。

类风湿关节炎别只关心炎症了,骨质疏松也不可小觑!

类风湿是骨质疏松的高危因素,在治疗时应该随时关注患者的骨骼健康。

类风湿常用6种中成药,一定要知晓!

一文梳理类风湿关节炎常用的中成药物。

王炎焱教授:类风关患者使用甲氨蝶呤效果不好怎么办?

甲氨蝶呤作为类风湿治疗的基石药物,为什么会有人使用甲氨蝶呤效果不明显?如何处理?